Skip to main content
. Author manuscript; available in PMC: 2013 Sep 16.
Published in final edited form as: Crit Care Clin. 2009 Apr;25(2):325–Contents. doi: 10.1016/j.ccc.2009.01.002

Table 6.

Systemic blood pressure

Characteristic As Treated (N = 714)
Per Protocol (N = 590)
PolyHeme (N = 350) Control (N = 364) PolyHeme (N = 279) Control (N = 311)
Markedly abnormal high SBP (>180 mm Hg)

 At admissiona 6 (2) 5 (1) 5 (2) 4 (1)

 At 6 h post injurya 11 (3) 5 (1) 10 (4) 4 (1)

 At admission or 6 h post inurya 16 (5) 10 (3) 14 (5) 8 (3)

Markedly abnormal high DBP (>105 mm Hg)

 At admissiona 23 (7) 18 (5) 17 (6) 14 (5)

 At 6 h post injurya 3 (1) 8 (2) 3 (1) 5 (2)

 At admission or 6 h post inurya 26 (7) 25 (7) 20 (7) 18 (6)

SBP at admission (mm Hg)b 115 (2) 113 (2) 115 (2) 113 (2)

SBP at 6 h post injury (mm Hg)b 129 (2)c 122 (2) 129 (2)c 122 (2)

DBP at admission (mm Hg)b 71 (1)c 68 (1) 71 (1) 68 (1)

DBP at 6 h post injury (mm Hg)b 73 (1)c 66 (1) 73 (1)c 66 (1)

Abbreviations: DPB, Diastolic blood pressure.

a

Values are expressed as n (%); percentages are based on the number of patients in each treatment group divided by number of patients who had nonmissing values.

b

Values are expressed as mean (SE).

c

P<.05 compared with Control.

Data from Moore EE, Moore FA, Fabian TC, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA Multicenter Trial. J Am Coll Surg 2009;208:1–13.